Item 2.02. Results of Operations and Financial Condition.
On January 25, 2021, Arbutus Biopharma Corporation (the "Company") issued a
press release (the "Press Release") announcing its 2021 corporate objectives and
providing certain estimated and projected financial information, including its
estimated cash, cash equivalents and investments as of December 31, 2020. The
amounts included in the Press Release are preliminary, have not been audited and
are subject to change upon completion of the Company's audited financial
statements for the year ended December 31, 2020. Additional information and
disclosures would be required for a more complete understanding of the Company's
financial position and results of operations as of December 31, 2020. A copy of
the Press Release is furnished as Exhibit 99.1 hereto.
On January 25, 2021, the Company posted an updated corporate presentation on its
website at www.arbutusbio.com (the "Corporate Presentation"), which included the
Company's estimated cash, cash equivalents and investments as of December 31,
2020. A copy of the Corporate Presentation is furnished as Exhibit 99.2 hereto.
Item 8.01. Other Events.
On January 25, 2021, the Company issued the Press Release, a copy of which is
attached hereto as Exhibit 99.1 and incorporated herein by reference.
A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 and
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
99.1 Press release dated January 25, 2021
99.2 Corporate Presentation dated January 2021
104 Cover page interactive data file (formatted as inline XBRL).
© Edgar Online, source Glimpses
